<p>, /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX)（&#34;Volition&#34;）是一家跨国表观遗传学公司，今天宣布将在 2025 年亚洲动物医学专业会议（AMAMS 2025）上进行两场关于其 Nu.Q®兽医癌症检测的口头报告，该会议是汇聚来自亚洲的领先兽医专业人士和专家的顶级活动。这两场报告展示了由 Masahiko Sato 博士（兽医医学博士，DACVIM（SAIM），DAiCVIM（IM））与富士胶卷兽医系统公司共同进行的两项临床研究的结果。Sato 博士是关键意见领袖，担任日本最大转诊医院之一的兽医专家急救中心内科服务主任。</p>
<p>AMAMS 2025 将在泰国举行。</p>
<p>Sato 博士对结果评论道：</p>
<p>&#34;Nu.Q®兽医癌症检测可能作为一种有价值的诊断工具，特别是在区分良性和恶性疾病方面，例如犬慢性肠病和胃肠道淋巴瘤。&#34;</p>
<p>富士胶卷兽医系统首席运营官 <strong>藤原清高</strong> 补充道：</p>
<p>&#34;我们很高兴领先的兽医 Sato 博士在日本采用了 Nu.Q®兽医癌症检测，不仅进行研究，还发布了具体的使用案例。我们相信这将进一步提高对该检测的认识并推动更广泛的应用。&#34;</p>
<p>报告内容：</p>
<p><strong>标题</strong>：&#34;血浆核小体浓度在区分犬慢性肠病与胃肠道淋巴瘤中的诊断效用&#34;</p>
<p><strong>报告人：</strong> 田边健太郎</p>
<p>** 日期和时间：**2025 年 6 月 5 日，星期四，下午 1:40 – 1:50（ICT）</p>
<p><strong>地点：</strong> 108 号房间</p>
<p><strong>主要结论：</strong> <strong>Nu.Q®兽医癌症检测可能作为一种有价值的诊断工具，用于区分 CE 与 GIL，特别是在中到大细胞 GIL 中观察到的水平特别高。</strong> <strong>标题</strong>：&#34;血浆核小体浓度作为犬鼻肿瘤生物标志物的评估&#34;</p>
<p><strong>报告人：</strong> 高桥千穗子</p>
<p>** 日期和时间：**2025 年 6 月 5 日，星期四，下午 3:30 – 3:40（ICT）</p>
<p><strong>地点：</strong> 108 号房间</p>
<p><strong>关于 Volition</strong></p>
<p>Volition 是一家专注于推进表观遗传学科学的跨国公司。Volition 致力于通过早期检测以及疾病和治疗监测，拯救生命并改善人类和动物在重大疾病中的预后。</p>
<p>通过其子公司，Volition 正在开发和商业化简单、易用、具有成本效益的血液检测，以帮助检测和监测一系列疾病，包括某些癌症和与 NETosis 相关的疾病，如脓毒症。早期检测和监测不仅有潜力延长患者的生命，还能改善他们的生活质量。</p>
<p>Volition 的研究和开发活动集中在比利时，在美国设有创新实验室和办公室，并在伦敦设有办公室。</p>
<p>在 Volition 网站上找到的内容不被视为本文件的一部分，也不应被视为本文件的一部分。该网站地址仅作为非活动文本引用包含在本文件中。</p>
<p><strong>媒体咨询：</strong> Louise Batchelor, Volition, mediarelations@volition.com+44 (0) 7557 774620</p>
<p><strong>投资者关系：</strong> Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com+1-212-915-2568</p>
<p><strong>安全港声明</strong></p>
<p>本新闻稿中的声明可能是根据《1933 年证券法》第 27A 条和《1934 年证券交易法》第 21E 条的定义所称的 “前瞻性声明”，涉及可能导致实际结果与预期或预测的前瞻性声明存在重大差异的风险和不确定性。诸如 “预计”、“预期”、“打算”、“计划”、“目标”、“瞄准”、“相信”、“寻求”、“估计”、“优化”、“潜在”、“目标”、“建议”、“可能”、“将”、“应该”、“或许”、“会” 等类似表达识别前瞻性声明。这些前瞻性声明涉及的主题包括，在实现里程碑事件后或在其到期之前行使与里程碑相关的认股权证，Volition 对收入机会和增长的预期，临床研究的数据时间、完成、成功和交付，出版的时间，Volition 成本降低措施的有效性，Volition 基于血液的诊断、预后和疾病监测测试的有效性和可用性，Volition 开发和成功商业化这些测试平台以早期检测癌症和其他疾病的能力，以及作为这些疾病的诊断、预后或疾病监测工具的能力，以及 Volition 在为其产品获得第三方许可和/或分销协议方面的成功。由于众多风险和不确定性，Volition 的实际结果可能与这些前瞻性声明中所指示的结果存在重大差异，包括但不限于测试其测试有效性的研究结果。例如，如果 Volition 未能开发和商业化诊断、预后或疾病监测产品，可能无法执行其运营计划。其他风险和不确定性包括 Volition 未能获得必要的监管许可或批准以分销和营销未来产品；市场未能接受 Volition 开发管道中的产品或 Volition 可能开发的任何其他诊断、预后或疾病监测产品；Volition 未能获得足够的知识产权保护；Volition 将面临激烈的竞争，且由于诊断和疾病监测市场的高度竞争性及其快速技术变革，Volition 的预期产品可能会变得过时；国内和国际经济的下滑；以及其他风险，包括在 Volition 最近的 10-K 表格年度报告和 10-Q 表格季度报告中识别的风险，以及 Volition 向证券交易委员会提交的其他文件。这些声明基于当前的预期、估计和关于 Volition 业务的预测，部分基于管理层做出的假设。这些声明并不保证未来的表现，并涉及难以预测的风险、不确定性和假设。前瞻性声明是在本发布之日作出的，除法律要求外，Volition 没有义务更新其前瞻性声明以反映未来事件或情况。</p>
<p>Nucleosomics™、Capture-PCR™、Capture-Seq™和 Nu.Q®及其各自的标志是 VolitionRx Limited 及其子公司的商标和/或服务标志。本新闻稿中提到的所有其他商标、服务标志和商号均为其各自所有者的财产。此外，除非另有说明，所有提及的 “$” 均指美国法定货币。</p>
<p>来源：VolitionRx Limited</p>

VNRX

<p>VolitionRx Limited（纽约证券交易所代码：VNRX）在泰国的亚洲动物医学专业会议（AMAMS 2025）上宣布了两场口头报告，展示其 Nu.Q® Vet 癌症检测。报告由佐藤雅彦博士主讲，重点在于区分犬类的良性和恶性疾病。关键发现表明，该检测可能有效区分犬类慢性肠病与胃肠道淋巴瘤。此次活动突显了 Volition 在推进表观遗传学和改善兽医学诊断工具方面的承诺</p>

<p>, /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (&#34;Volition&#34;), a multi-national epigenetics company, today announces two oral presentations featuring its Nu.Q® Vet Cancer Test at the Asian Meeting of Animal Medicine Specialties (AMAMS 2025), a premier event bringing together leading veterinary professionals and experts from across Asia.The two presentations feature results from two clinical studies conducted by Dr Masahiko Sato, DVM, PhD, DACVIM (SAIM), DAiCVIM (IM) in conjunction with FujiFilm Vet Systems. Dr Sato, a key opinion leader is Chief of Internal Medicine Service at the Veterinary Specialists Emergency Center, one of the largest referral hospitals in Japan.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX)（&#34;Volition&#34;）是一家跨国表观遗传学公司，今天宣布将在 2025 年亚洲动物医学专业会议（AMAMS 2025）上进行两场关于其 Nu.Q®兽医癌症检测的口头报告，该会议是汇聚来自亚洲的领先兽医专业人士和专家的顶级活动。这两场报告展示了由 Masahiko Sato 博士（兽医医学博士，DACVIM（SAIM），DAiCVIM（IM））与富士胶卷兽医系统公司共同进行的两项临床研究的结果。Sato 博士是关键意见领袖，担任日本最大转诊医院之一的兽医专家急救中心内科服务主任。</p>
</div><p>AMAMS 2025 is taking place in Thailand.</p>
<div class="lb-trans"><p>AMAMS 2025 将在泰国举行。</p>
</div><p>Commenting on the results <strong>Dr Sato</strong> said:</p>
<div class="lb-trans"><p>Sato 博士对结果评论道：</p>
</div><p>&#34;The Nu.Q® Vet Cancer Test may serve as a valuable diagnostic tool, particularly for differentiating between benign and malignant conditions such as Canine Chronic Enteropathy and Gastrointestinal Lymphoma.&#34;</p>
<div class="lb-trans"><p>&#34;Nu.Q®兽医癌症检测可能作为一种有价值的诊断工具，特别是在区分良性和恶性疾病方面，例如犬慢性肠病和胃肠道淋巴瘤。&#34;</p>
</div><p><strong>Kiyotaka Fujiwara,</strong> Chief Operating Officer at Fujifilm Vet Systems, added:</p>
<div class="lb-trans"><p>富士胶卷兽医系统首席运营官 <strong>藤原清高</strong> 补充道：</p>
</div><p>&#34;We are delighted that leading veterinarian Dr Sato has adopted the Nu.Q® Vet Cancer Test in Japan, and not only researching, but publishing specific use cases. We believe this will further raise the awareness of the test and drive wider adoption.&#34;</p>
<div class="lb-trans"><p>&#34;我们很高兴领先的兽医 Sato 博士在日本采用了 Nu.Q®兽医癌症检测，不仅进行研究，还发布了具体的使用案例。我们相信这将进一步提高对该检测的认识并推动更广泛的应用。&#34;</p>
</div><p>The presentations:</p>
<div class="lb-trans"><p>报告内容：</p>
</div><p><strong>Title</strong>: &#34;Diagnostic Utility of Plasma Nucleosome Concentration in Differentiating Canine Chronic Enteropathy from Gastrointestinal Lymphoma&#34;</p>
<div class="lb-trans"><p><strong>标题</strong>：&#34;血浆核小体浓度在区分犬慢性肠病与胃肠道淋巴瘤中的诊断效用&#34;</p>
</div><p><strong>Presenter:</strong> Kentaro Nabeshima</p>
<div class="lb-trans"><p><strong>报告人：</strong> 田边健太郎</p>
</div><p><strong>Date and Time:</strong> Thursday, June 5, 2025, 1:40PM – 1:50PM (ICT)</p>
<div class="lb-trans"><p>** 日期和时间：**2025 年 6 月 5 日，星期四，下午 1:40 – 1:50（ICT）</p>
</div><p><strong>Venue:</strong> Room 108</p>
<div class="lb-trans"><p><strong>地点：</strong> 108 号房间</p>
</div><p><strong>Key Conclusion:</strong> <strong>Nu.Q® Vet Cancer Test may serve as a valuable diagnostic tool for distinguishing CE from GIL, with particularly high levels observed in medium-to-large cell GIL.</strong> <strong>Title</strong>: &#34;Evaluation of Plasma Nucleosome Concentrations as a Biomarker for Canine Nasal Tumors&#34;</p>
<div class="lb-trans"><p><strong>主要结论：</strong> <strong>Nu.Q®兽医癌症检测可能作为一种有价值的诊断工具，用于区分 CE 与 GIL，特别是在中到大细胞 GIL 中观察到的水平特别高。</strong> <strong>标题</strong>：&#34;血浆核小体浓度作为犬鼻肿瘤生物标志物的评估&#34;</p>
</div><p><strong>Presenter:</strong> Chihoko Takahashi</p>
<div class="lb-trans"><p><strong>报告人：</strong> 高桥千穗子</p>
</div><p><strong>Date and Time:</strong> Thursday, June 5, 2025, 3:30PM – 3:40PM (ICT)</p>
<div class="lb-trans"><p>** 日期和时间：**2025 年 6 月 5 日，星期四，下午 3:30 – 3:40（ICT）</p>
</div><p><strong>Venue:</strong> Room 108</p>
<div class="lb-trans"><p><strong>地点：</strong> 108 号房间</p>
</div><p><strong>About Volition</strong></p>
<div class="lb-trans"><p><strong>关于 Volition</strong></p>
</div><p>Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.</p>
<div class="lb-trans"><p>Volition 是一家专注于推进表观遗传学科学的跨国公司。Volition 致力于通过早期检测以及疾病和治疗监测，拯救生命并改善人类和动物在重大疾病中的预后。</p>
</div><p>Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.</p>
<div class="lb-trans"><p>通过其子公司，Volition 正在开发和商业化简单、易用、具有成本效益的血液检测，以帮助检测和监测一系列疾病，包括某些癌症和与 NETosis 相关的疾病，如脓毒症。早期检测和监测不仅有潜力延长患者的生命，还能改善他们的生活质量。</p>
</div><p>Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.</p>
<div class="lb-trans"><p>Volition 的研究和开发活动集中在比利时，在美国设有创新实验室和办公室，并在伦敦设有办公室。</p>
</div><p>The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.</p>
<div class="lb-trans"><p>在 Volition 网站上找到的内容不被视为本文件的一部分，也不应被视为本文件的一部分。该网站地址仅作为非活动文本引用包含在本文件中。</p>
</div><p><strong>Media Enquiries:</strong> Louise Batchelor, Volition, mediarelations@volition.com+44 (0) 7557 774620</p>
<div class="lb-trans"><p><strong>媒体咨询：</strong> Louise Batchelor, Volition, mediarelations@volition.com+44 (0) 7557 774620</p>
</div><p><strong>Investor Relations:</strong> Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com+1-212-915-2568</p>
<div class="lb-trans"><p><strong>投资者关系：</strong> Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com+1-212-915-2568</p>
</div><p><strong>Safe Harbor Statement</strong></p>
<div class="lb-trans"><p><strong>安全港声明</strong></p>
</div><p>Statements in this press release may be &#34;forward-looking statements&#34; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as &#34;expects,&#34; &#34;anticipates,&#34; &#34;intends,&#34; &#34;plans,&#34; &#34;aims,&#34; &#34;targets,&#34; &#34;believes,&#34; &#34;seeks,&#34; &#34;estimates,&#34; &#34;optimizing,&#34; &#34;potential,&#34; &#34;goal,&#34; &#34;suggests,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;may,&#34; &#34;will&#34; and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, the exercise of the milestone-linked warrants upon the achievement of such milestone events or otherwise prior to their expiration, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, the effectiveness of Volition's cost reduction measures, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.</p>
<div class="lb-trans"><p>本新闻稿中的声明可能是根据《1933 年证券法》第 27A 条和《1934 年证券交易法》第 21E 条的定义所称的 “前瞻性声明”，涉及可能导致实际结果与预期或预测的前瞻性声明存在重大差异的风险和不确定性。诸如 “预计”、“预期”、“打算”、“计划”、“目标”、“瞄准”、“相信”、“寻求”、“估计”、“优化”、“潜在”、“目标”、“建议”、“可能”、“将”、“应该”、“或许”、“会” 等类似表达识别前瞻性声明。这些前瞻性声明涉及的主题包括，在实现里程碑事件后或在其到期之前行使与里程碑相关的认股权证，Volition 对收入机会和增长的预期，临床研究的数据时间、完成、成功和交付，出版的时间，Volition 成本降低措施的有效性，Volition 基于血液的诊断、预后和疾病监测测试的有效性和可用性，Volition 开发和成功商业化这些测试平台以早期检测癌症和其他疾病的能力，以及作为这些疾病的诊断、预后或疾病监测工具的能力，以及 Volition 在为其产品获得第三方许可和/或分销协议方面的成功。由于众多风险和不确定性，Volition 的实际结果可能与这些前瞻性声明中所指示的结果存在重大差异，包括但不限于测试其测试有效性的研究结果。例如，如果 Volition 未能开发和商业化诊断、预后或疾病监测产品，可能无法执行其运营计划。其他风险和不确定性包括 Volition 未能获得必要的监管许可或批准以分销和营销未来产品；市场未能接受 Volition 开发管道中的产品或 Volition 可能开发的任何其他诊断、预后或疾病监测产品；Volition 未能获得足够的知识产权保护；Volition 将面临激烈的竞争，且由于诊断和疾病监测市场的高度竞争性及其快速技术变革，Volition 的预期产品可能会变得过时；国内和国际经济的下滑；以及其他风险，包括在 Volition 最近的 10-K 表格年度报告和 10-Q 表格季度报告中识别的风险，以及 Volition 向证券交易委员会提交的其他文件。这些声明基于当前的预期、估计和关于 Volition 业务的预测，部分基于管理层做出的假设。这些声明并不保证未来的表现，并涉及难以预测的风险、不确定性和假设。前瞻性声明是在本发布之日作出的，除法律要求外，Volition 没有义务更新其前瞻性声明以反映未来事件或情况。</p>
</div><p>Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to &#34;$&#34; refer to the legal currency of the United States of America.</p>
<div class="lb-trans"><p>Nucleosomics™、Capture-PCR™、Capture-Seq™和 Nu.Q®及其各自的标志是 VolitionRx Limited 及其子公司的商标和/或服务标志。本新闻稿中提到的所有其他商标、服务标志和商号均为其各自所有者的财产。此外，除非另有说明，所有提及的 “$” 均指美国法定货币。</p>
</div><p>SOURCE VolitionRx Limited</p>
<div class="lb-trans"><p>来源：VolitionRx Limited</p>
</div>

Volition 宣布将在亚洲动物医学专业会议上进行两场口头报告 | Volitionrx 股票新闻